Oncoclínicas do Brasil Serviços Médicos S.A. (ONCO3) reported in a material fact notice this Thursday, August 27, 2026, that the Comissão de Valores Mobiliários (CVM) decided, in a meeting held on August 25, 2026, to grant appeals against the previous understanding of the Superintendência de Registro de Valores Mobiliários (SRE) regarding the non-applicability of the statutory tender offer (OPA) set forth in Article 39 of its Bylaws, ordering that the tender offer be carried out.
According to the decision of the CVM Board, the date of the triggering event was defined as November 4, 2024, based on which the acquisition price of the shares must be calculated and subsequently updated by the Selic rate, in accordance with the applicable regulation. The price must be calculated in accordance with Article 39, paragraph 1, of the company’s Bylaws.
The CVM set a maximum period of 60 days for the tender offer to be carried out by Centaurus Capital L.P., which ends on October 24, 2026. The beneficiaries of the offer will be Oncoclínicas shareholders qualified up to the eve of the auction, pursuant to paragraph 1 of Article 25 of CVM Resolution No. 215/2024.
The Board also decided to set aside the exceptions provided for in paragraphs 7 and 8 of Article 39 of the company’s Bylaws.
